发明授权
US07605179B2 Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders
有权
萘醌衍生物作为tau聚集的抑制剂用于治疗阿尔茨海默病和相关的神经变性疾病
- 专利标题： Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders
- 专利标题（中）： 萘醌衍生物作为tau聚集的抑制剂用于治疗阿尔茨海默病和相关的神经变性疾病
-
申请号： US10483266申请日： 2002-07-16
-
公开(公告)号： US07605179B2公开(公告)日： 2009-10-20
- 发明人: Claude Michel Wischik , David Horsley , Janet Elizabeth Rickard , Charles Robert Harrington
- 申请人： Claude Michel Wischik , David Horsley , Janet Elizabeth Rickard , Charles Robert Harrington
- 申请人地址： SG Singapore
- 专利权人： Wista Laboratories Ltd.
- 当前专利权人： Wista Laboratories Ltd.
- 当前专利权人地址： SG Singapore
- 代理机构： Foley & Lardner LLP
- 优先权： GB0117326.9 20010716
- 国际申请： PCT/GB02/03269 WO 20020716
- 国际公布： WO03/007933 WO 20030130
- 主分类号： A61K31/23
- IPC分类号： A61K31/23 ; A01N37/00 ; A01N35/00
摘要：
Provided are napthoquinone-type compounds which can be used to modulate the aggregation of protein (e.g. tau) associated with neurodegenerative disease (e.g. Alzheimer's disease). Structure-function characteristics for oxidised and reduced napthoquinone-type compounds, such as menadione-related compounds, are disclosed. The invention further provides methods of treatment or prophylaxis of neurodegenerative diseases and/or clinical dementias based on the compounds.
公开/授权文献
信息查询
